The results of this review suggest that FIT may be effective as a method of screening for CRC and advanced adenomas, and that FIT may be more effective when compared to other screening tests, such as gFOBT. In particular, the HemeSelect, FlexSure OBT, and OC-Sensor Micro FITs have demonstrated improved diagnostic performance characteristics compared with the gFOBT. All included studies that compared participation rates of FIT with other screening tests demonstrated that FIT had higher completion rates than the other tests, including gFOBT. The type of FIT and associated costs, the appropriate hemoglobin cut-off to use, and the capacity for follow-up by colonoscopy or flexible sigmoidoscopy may contribute to deciding if FIT is an appropriate CRC screening tool.